{"id":358027,"date":"2023-05-17T13:05:09","date_gmt":"2023-05-17T11:05:09","guid":{"rendered":"https:\/\/medizinonline.com\/breast-carcinoma-with-disseminated-osteoblastic-metastasis\/"},"modified":"2023-05-17T13:07:54","modified_gmt":"2023-05-17T11:07:54","slug":"breast-carcinoma-with-disseminated-osteoblastic-metastasis","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/breast-carcinoma-with-disseminated-osteoblastic-metastasis\/","title":{"rendered":"Breast carcinoma with disseminated osteoblastic metastasis."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>More than 70% of breast cancer sufferers are diagnosed as hormone receptor positive and HER2 negative (HR+\/HER2-) [1]. Clinical trial data show that a therapy combination with CDK4\/6 inhibitors can increase progression-free survival (PFS) and overall survival (OS) [2-5]. This was also the case in the presented case of an 81-year-old female patient with recurrent HR+\/HER2- breast carcinoma.<\/strong><\/p>\n\n<!--more-->\n\n<p class=\"wp-block-paragraph\">Watch the video to see all details of the case presented by PD Marcus Vetter, MD, Center of Oncology &amp; Hematology, Cantonal Hospital Baselland.<\/p>\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n<figure class=\"wp-block-embed is-type-video is-provider-vimeo wp-block-embed-vimeo wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Vetter_DE_FINAL\" data-src=\"https:\/\/player.vimeo.com\/video\/814171020?h=cd373566bd&amp;dnt=1&amp;app_id=122963\" width=\"1160\" height=\"653\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"1\"><\/iframe>\n<\/div><\/figure>\n\n<p class=\"wp-block-paragraph\">References<\/p>\n\n<p class=\"wp-block-paragraph\">1. Blows, F.M., et al, <em>Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies<\/em>. PLoS Med, 2010. <strong>7<\/strong>(5): p. e1000279.<\/p>\n\n<p class=\"wp-block-paragraph\">2. Goyal, R.K., et al, <em>Overall survival associated with CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study<\/em>. Cancer, 2023. <strong>129<\/strong>(7): p. 1051-1063.<\/p>\n\n<p class=\"wp-block-paragraph\">3. Goyal, R.K., et al, <em>Impact of CDK4\/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+\/HER2- metastatic breast cancer in the United States<\/em>. Breast Cancer Res Treat, 2023. <strong>198<\/strong>(1): p. 159-166.<\/p>\n\n<p class=\"wp-block-paragraph\">4. Li, J., et al, <em>Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.<\/em>Breast Cancer Res Treat, 2020. <strong>180<\/strong>(1): p. 21-32.<\/p>\n\n<p class=\"wp-block-paragraph\">5. Elfgen, C. and V. Bjelic-Radisic, <em>Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4\/6 Inhibitor Therapy and beyond Treatment Options.<\/em>Cancers (Basel), 2021. <strong>13<\/strong>(23).<\/p>\n\n<p class=\"wp-block-paragraph\">The references are available on request.<\/p>\n\n<p class=\"wp-block-paragraph\">The current Ibrance\u00ae product information can be found at<a> www.swissmedicinfo.ch.<\/a> <\/p>\n\n<p class=\"wp-block-paragraph\">PP-IBR-CHE-0423 Apr 2023<\/p>\n\n<p class=\"wp-block-paragraph\">Post online since 17.05.2023<\/p>\n","protected":false},"excerpt":{"rendered":"<p>More than 70% of breast cancer sufferers are diagnosed as hormone receptor positive and HER2 negative (HR+\/HER2-) [1]. Clinical trial data show that a therapy combination with CDK4\/6 inhibitors can&hellip;<\/p>\n","protected":false},"author":14,"featured_media":355331,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Patient case ","footnotes":""},"category":[11370,11323,11548],"tags":[],"powerkit_post_featured":[],"class_list":["post-358027","post","type-post","status-publish","format-standard","has-post-thumbnail","category-oncology","category-partner-content-en","category-rx-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-18 14:38:38","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":358026,"slug":"carcinome-mammaire-avec-metastases-osteoblastiques-disseminees","post_title":"Carcinome mammaire avec m\u00e9tastases ost\u00e9oblastiques diss\u00e9min\u00e9es","href":"https:\/\/medizinonline.com\/fr\/carcinome-mammaire-avec-metastases-osteoblastiques-disseminees\/"},"it_IT":{"locale":"it_IT","id":358029,"slug":"carcinoma-mammario-con-metastasi-osteoblastiche-disseminate","post_title":"Carcinoma mammario con metastasi osteoblastiche disseminate","href":"https:\/\/medizinonline.com\/it\/carcinoma-mammario-con-metastasi-osteoblastiche-disseminate\/"},"pt_PT":{"locale":"pt_PT","id":358030,"slug":"carcinoma-da-mama-com-metastases-osteoblasticas-disseminadas","post_title":"Carcinoma da mama com met\u00e1stases osteobl\u00e1sticas disseminadas","href":"https:\/\/medizinonline.com\/pt-pt\/carcinoma-da-mama-com-metastases-osteoblasticas-disseminadas\/"},"es_ES":{"locale":"es_ES","id":358028,"slug":"carcinoma-de-mama-con-metastasis-osteoblastica-diseminada","post_title":"Carcinoma de mama con met\u00e1stasis osteobl\u00e1stica diseminada","href":"https:\/\/medizinonline.com\/es\/carcinoma-de-mama-con-metastasis-osteoblastica-diseminada\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/358027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=358027"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/358027\/revisions"}],"predecessor-version":[{"id":358031,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/358027\/revisions\/358031"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/355331"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=358027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=358027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=358027"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=358027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}